Febuxostat is a xanthine oxidase inhibitor used for treating gout caused by excessive levels of uric acid in the blood (hyperuricemia). Uric acid is formed from the breakdown of certain chemicals (purines) in the body. Hyperuricemia occurs when the body produces more uric acid than it can eliminate. The uric acid forms crystals in joints (gouty arthritis) and tissues, causing inflammation and pain. Elevated blood uric acid levels also can cause kidney disease and kidney stones. Febuxostat prevents the production of uric acid by blocking the activity of the enzyme (xanthine oxidase) that converts purines to uric acid. Uric acid levels may fall to target treatment levels within two weeks. Febuxostat and allopurinol (Zyloprim) are similar in how they work, but the maximum dose of febuxostat is more effective in reducing uric acid levels. The FDA approved febuxostat in February 2009.e g
oal for long-term management of gout.
Disclaimer
The opinions expressed in this blog must not be considered in lieu of medical advice. They represent opinions of the blog writer and resources. The articles are for information purpose only, and a formal medical advice should be sought before undergoing any treatment.
No comments:
Post a Comment